Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Ketamine on Epigenetic Age (IKEA)
NCT05294835Phase 2Unknown
- Sponsor
- TruDiagnostic
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), post-traumatic stress disorder (PTSD), sponsored by TruDiagnostic. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05294835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294835.